Phenotypic and Genotypic Characteristics of Clostridium difficile Isolates in Patients with Type 2 Diabetes in Iran

References

• Luo Y, Zhang W, Cheng JW, et al. Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China. Infect Drug Resist. 2018;11:489–500. doi:10.2147/IDR.S15272429670381
   PubMed Web of Science ®Google Scholar
• Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control. 2011;39(3):194–198. doi:10.1016/j.ajic.2010.08.01721349600
   PubMed Web of Science ®Google Scholar
• Azimirad M, Krutova M, Nyc O, et al. Molecular typing of Clostridium difficile isolates cultured from patient stool samples and gastroenterological medical devices in a single Iranian hospital. Anaerobe. 2017;47:125–128. doi:10.1016/j.anaerobe.2017.05.00428501554
   PubMed Web of Science ®Google Scholar
• Gillespie W, Marya N, Fahed J, Leslie G, Patel K, Cave DR. Clostridium difficile in inflammatory bowel disease: a retrospective study. Gastroenterol Res Pract. 2017;2017:4803262. doi:10.1155/2017/480326229109735
   PubMed Web of Science ®Google Scholar
• Olanipekun TO, Salemi JL, Mejia de Grubb MC, Gonzalez SJ, Zoorob RJ. Clostridium difficile infection in patients hospitalized with type 2 diabetes mellitus and its impact on morbidity, mortality, and the costs of inpatient care. Diabetes Res Clin Pract. 2016;116:68–79. doi:10.1016/j.diabres.2016.04.02127321318
   PubMedGoogle Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi:10.1016/j.diabres.2018.02.02329496507
   PubMed Web of Science ®Google Scholar
• Kaiser AB, Zhang N, Van der Pluijm W. Global prevalence of type 2 diabetes over the next ten years (2018-2028). Am Diabetes Assoc. 2018;67:202–LB. doi:10.2337/db18-202-LB
   Web of Science ®Google Scholar
• Esteghamati A, Larijani B, Aghajani MH, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of national program for prevention and control of diabetes (NPPCD-2016). Sci Rep. 2017;7(1):13461. doi:10.1038/s41598-017-13379-z29044139
   PubMed Web of Science ®Google Scholar
• Qu HQ, Jiang ZD. Clostridium difficile infection in diabetes. Diabetes Res Clin Pract. 2014;105(3):285–294. doi:10.1016/j.diabres.2014.06.00225015315
   PubMedGoogle Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48. doi:10.1093/cid/cix108529462280
   PubMed Web of Science ®Google Scholar
• care ADAJD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement1):S81–S90. doi:10.2337/dc14-S08124357215
   PubMed Web of Science ®Google Scholar
• Hassan S, Rahman R, Huda N, Wan Bebakar W, Lee Y. Hospital-acquired Clostridium difficile infection among patients with type 2 diabetes mellitus in acute medical wards. J JR Coll Physicians Edinb. 2013;43(2):103–107. doi:10.4997/JRCPE.2013.203
   Google Scholar
• Hashemi A, Shojaei H, Heidarieh P, Aslani MM, Naser AD. Genetic diversity of Iranian clinical isolates of Mycobacterium tuberculosis. New Microbiol. 2012;35(1):61–65.22378554
   PubMedGoogle Scholar
• Barbut F, Mario N, Delmée M, Gozian J. Genomic fingerprinting of Clostridium difficile isolates by using a random amplified polymorphic DNA (RAPD) assay. FEMS Microbiol Lett. 1993;114(2):161–166. doi:10.1111/j.1574-6968.1993.tb06567.x8282184
   PubMed Web of Science ®Google Scholar
• Pitcher D, Saunders N, Owen R. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett Appl Microbiol. 1989;8(4):151–156. doi:10.1111/j.1472-765X.1989.tb00262.x
   Web of Science ®Google Scholar
• Lemee L, Dhalluin A, Testelin S, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol. 2004;42(12):5710–5714. doi:10.1128/JCM.42.12.5710-5714.200415583303
   PubMed Web of Science ®Google Scholar
• Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett. 2000;186(2):307–312. doi:10.1111/fml.2000.186.issue-210802189
   PubMed Web of Science ®Google Scholar
• Griffiths D, Fawley W, Kachrimanidou M, et al. Multilocus sequence typing of Clostridium difficile. J Clin Microbiol. 2010;48(3):770–778. doi:10.1128/JCM.01796-0920042623
   PubMed Web of Science ®Google Scholar
• Mobasherizadeh S, Shojaei H, Havaei SA, et al. Application of the Random Amplified Polymorphic DNA (RAPD) fingerprinting to analyze genetic variation in community associated-methicillin resistant staphylococcus aureus (CA-MRSA) isolates in Iran. Glob J Health Sci. 2016;8(8):53822.27045409
   PubMedGoogle Scholar
• Nash JJIfBS. DNAfrag, Version 3.03. Ottawa (ON): National Research Council of Canada; 1991.
   Google Scholar
• Testing ECoAS. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, valid from 2019-01-01.
   Google Scholar
• Wayne P. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and laboratory standards institute; 2011.
   Google Scholar
• Eliakim-Raz N, Fishman G, Yahav D, et al. Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case–control study. Eur J Clin Microbiol Infect Dis. 2015;34(6):1201–1205. doi:10.1007/s10096-015-2348-325686730
   PubMed Web of Science ®Google Scholar
• Cheng VC, Yam WC, Chan JF, To KK, Ho PL, Yuen KY. Clostridium difficile ribotype 027 arrives in Hong Kong. Int J Antimicrob Agents. 2009;34(5):492–493. doi:10.1016/j.ijantimicag.2009.04.00419464857
   PubMed Web of Science ®Google Scholar
• Shoaei P, Shojaei H, Jalali M, et al. Clostridium difficile isolated from faecal samples in patients with ulcerative colitis. BMC Infect Dis. 2019;19(1):361. doi:10.1186/s12879-019-3965-831039738
   PubMed Web of Science ®Google Scholar
• Shoaei P, Shojaei H, Khorvash F, et al. Clostridium difficile infection in cancer patients with hospital acquired diarrhea at the teaching hospitals in Iran: multilocus sequence typing analysis (MLST) and Antimicrobial resistance pattern. Anni Ig. 2019;31(4):365–373. doi:10.7416/ai.2019.2298
   Web of Science ®Google Scholar
• Shoaei P, Shojaei H, Khorvash F, et al. Molecular epidemiology of Clostridium difficile infection in Iranian hospitals. Antimicrob Resist Infect Control. 2019;8(1):12. doi:10.1186/s13756-018-0454-630675339
   PubMed Web of Science ®Google Scholar
• Jin D, Luo Y, Huang C, et al. Molecular epidemiology of clostridium difficile infection in hospitalized patients in Eastern China. J Clin Microbiol. 2017;55(3):801–810. doi:10.1128/JCM.01898-1627974547
   PubMed Web of Science ®Google Scholar
• Azimirad M, Alebouyeh M, Rashidan M, Aslani MM, Zali MR. Comparison of common molecular typing methods for differentiation of clostridium difficile strains in the study of hospital acquired infections. Kowsarmedical. 2018;13(5):e61030–e61030.
   Google Scholar
• Mutters NT, Heeg K, Späth I, Henny N, Günther F. Improvement of infection control management by routine molecular evaluation of pathogen clusters. Diagn Microbiol Infect Dis. 2017;88(1):82–87. doi:10.1016/j.diagmicrobio.2017.01.01328189284
   PubMedGoogle Scholar
• Goudarzi M, Goudarzi H, Alebouyeh M, et al. Antimicrobial susceptibility of clostridium difficile clinical isolates in iran. Iran Red Crescent Med J. 2013;15(8):704–711. doi:10.5812/ircmj24578839
   PubMed Web of Science ®Google Scholar
• Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21(2):164–170. doi:10.1016/j.cmi.2014.08.01725658560
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–858. doi:10.1038/nm.434528530702
   PubMed Web of Science ®Google Scholar